The FDA has granted accelerated approval for Wegovy for the treatment of noncirrhotic MASH with moderate to advanced liver fibrosis in adults.

Regulations aiming to lower the cost of vital medicines will instead end up restricting access and disincentivizing R&D.

GLP-1 weight-loss drugs are creating “mortality slippage” in life insurance which is a costly problem that's forcing insurers to rethink how they underwrite.

Danish drugmaker Novo Nordisk (NVO) has implemented a hiring freeze, which will apply across all markets and departments, ...

Novo Nordisk just pulled Wegovy from a major telehealth platform over safety concerns about knockoff versions. Here's what ...

A doctor has revealed the truth behind what is being dubbed the 'Ozempic vulva' as the drug surges in popularity.

The weight loss drug, which was previously also used to treat diabetes, may be having an unexpected impact on a rather sensitive body part ...

Non-arteritic anterior ischaemic optic neuropathy, or NAION, is a rare but devastating eye condition that occurs when blood ...

Wegovy-maker Novo Nordisk has implemented a global hiring freeze covering job roles that are not critical for its business, ...

Wegovy-maker Novo Nordisk has implemented a global hiring freeze, which covers job roles that are not critical for its ...

The side effect is rare, according to a new study, but is also the subject of multiple lawsuits, including two filed by Long ...

The U.S. Food and Drug Administration approved the obesity drug Wegovy for people with the chronic liver disease known as ...